-
公开(公告)号：EP1296942A1
公开(公告)日：2003-04-02
申请号：EP01943189.9
申请日：2001-06-21
申请人： Novo Nordisk A/S
发明人： JOERGENSEN, Anker, Steen , CHRISTENSEN, Inge, Thoeger , KODRA, Janos, Tibor , MADSEN, Peter , BEHRENS, Carsten , SAMS, Christian , LAU, Jesper
IPC分类号： C07C275/24 , C07C275/28 , C07C237/20 , C07C237/32 , C07D209/48 , C07D213/36 , C07D277/62 , A61K31/166 , A61K31/167 , A61K31/17 , A61K31/429 , A61K31/4035 , A61K31/44 , A61P3/04 , A61P3/10
CPC分类号： C07D209/48 , C07C237/42 , C07C275/28 , C07C275/30 , C07C275/34 , C07C275/42 , C07C317/42 , C07C323/44 , C07C2601/14 , C07C2601/16 , C07D209/08 , C07D209/42 , C07D213/40 , C07D213/75 , C07D213/82 , C07D257/04 , C07D263/57 , C07D271/06 , C07D277/28 , C07D277/66 , C07D277/82 , C07D307/68 , C07D319/08 , C07D333/20 , C07D333/36 , C07D333/68 , C07D513/04
摘要： A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any diseases and disorders, wherein a glucagon antagonistic action is beneficial, such as hyperglycemia, Type 1 diabetes, Type 2 diabetes, disorders of the lipid metabolism and obesity.
摘要翻译： 一类新颖的化合物，其作用是拮抗胰高血糖素激素对胰高血糖素受体的作用。 由于它们对胰高血糖素受体的拮抗作用，所述化合物可适用于治疗和/或预防任何疾病和病症，其中胰高血糖素拮抗作用是有益的，例如高血糖症，1型糖尿病，2型糖尿病， 脂质代谢和肥胖。
-
公开(公告)号：EP1991576A1
公开(公告)日：2008-11-19
申请号：EP07712327.1
申请日：2007-02-27
申请人： Novo Nordisk A/S
发明人： FYNBO, Charlotte, Harkjaer , JONASSEN, Ib , KJELDSEN, Thomas, Børglum , MADSEN, Peter , GARIBAY, Patrick, William , KODRA, Janos, Tibor , HOEG-JENSEN, Thomas , TAGMOSE, Tina, Møller
摘要： The present invention is related to insulin derivatives having a side chain attached to an ϵ-amino group of a Lys residue present in the A-chain or to an ϵ -amino group of a Lys residue in the B-chain.
-
公开(公告)号：EP1463715A1
公开(公告)日：2004-10-06
申请号：EP02804158.0
申请日：2002-11-28
申请人： NOVO NORDISK A/S
发明人： KODRA, Janos, Tibor , MADSEN, Peter , LAU, Jesper , J RGENSEN, Anker, Steen , CHRISTENSEN, Inge, Th ger
IPC分类号： C07C235/84 , C07C323/62 , A61K31/16 , A61K31/10 , A61P3/10
CPC分类号： A61K45/06 , A61K31/195 , A61K31/198 , A61K31/41 , A61K31/4439 , A61K2300/00
摘要： Novel compounds that act to antagonize the action of the glucagon peptide hormone on the glucagon receptor. More particularly, it relates to glucagon antagonists or inverse agonists.
-
公开(公告)号：EP1991576B1
公开(公告)日：2010-09-29
申请号：EP07712327.1
申请日：2007-02-27
申请人： Novo Nordisk A/S
-
公开(公告)号：EP1147094A1
公开(公告)日：2001-10-24
申请号：EP00900499.5
申请日：2000-01-14
发明人： TENG, Min , TRUESDALE, Larry, Kenneth , BHUMRALKAR, Dilip , KIEL, Dan , JOHNSON, Michael, D. , THOMAS, Christine , JORGENSEN, Anker, Steen , MADSEN, Peter , OLESEN, Preben, Houlberg , KNUDSEN, Liselotte, Bjerre , PETTERSON, Ingrid, Vivika , CORNELIS DE JONG, Johannes , BEHRENS, Carsten , KODRA, Janos, Tibor , LAU, Jesper
IPC分类号： C07D241/00 , A61K31/498 , A61P3/04 , A61P3/10
CPC分类号： C07D401/04 , C07D241/42 , C07D241/44 , C07D401/12 , C07D403/04 , C07D403/12 , C07D405/12 , C07D409/12 , C07D413/12 , C07D417/12 , C07D487/04 , C07D491/10
摘要： Novel non-peptide GLP-1 agonists, pharmaceutical compositions comprising them, use of the non-peptide GLP-1 agonists for the preparation of pharmaceutical compositions and methods for the treatment and/or prevention of disorders and diseases wherein an activation of the human GLP-1 receptor is beneficial, especially metabolic disorders such as IGT, Type 1 diabetes, Type 2 diabetes and obesity.
-
-
-
-
搜索结果
5 条记录 (耗时 0.013 秒)
